US Stock Market Closed

Dashboard

Oncolytics Biotech, Inc. (ONCY)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity
Analyst Opinion

B

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

CEO

Matthew C. Coffey

Employees

23

Industry

-

Sector

-

Headquarters

Calgary

Exchange

NASDAQ

Summary Stats

Market Cap

72.5M

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 4 analysts

High

$11.00

Average

$8.79

Low

$6.00

Ratings calculated by 3 analysts

Buy

3

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q2 2022

Last Earnings

Missed by $0.00

Actual

-$0.07 +-0.0%

Consensus

-0.07

Report Date

Year Ago

-0.11

Year Ago Change %

Up 36%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites